Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
Journal Information
Full Title: Br J Clin Pharmacol
Abbreviation: Br J Clin Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST P.J., C.L., E.S., M.B.J., M.B. and C.dM. are paid consultants of Sobi. M.B.J. has participated in scientific advisory board meetings for Sobi. F.L. has acted as an unpaid consultant to Sobi, reviewing efficacy and safety data from clinical studies. M.B. and C.dM. are former employees of Sobi."
Funding Disclosure
Evidence found in paper:
"Funding information European Commission Directorate‐General for Research & Innovation; Swedish Orphan Biovitrum AB (publ)"
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025